MA37742B1 - Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments - Google Patents
Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicamentsInfo
- Publication number
- MA37742B1 MA37742B1 MA37742A MA37742A MA37742B1 MA 37742 B1 MA37742 B1 MA 37742B1 MA 37742 A MA37742 A MA 37742A MA 37742 A MA37742 A MA 37742A MA 37742 B1 MA37742 B1 MA 37742B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- medicaments
- tetraene
- derivatives
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
La présente invention concerne des inhibiteurs de akr1c3 et des procédés pour les préparer, ainsi que leur utilisation pour traiter et/ou prévenir des maladies et pour fabriquer des médicaments destinés à traiter et/ou à prévenir des maladies, en particulier les troubles hémorragiques et l'endométriose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012211970 | 2012-07-10 | ||
PCT/EP2013/064257 WO2014009274A1 (fr) | 2012-07-10 | 2013-07-05 | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37742A1 MA37742A1 (fr) | 2016-05-31 |
MA37742B1 true MA37742B1 (fr) | 2016-12-30 |
Family
ID=48748225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37742A MA37742B1 (fr) | 2012-07-10 | 2015-01-07 | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments |
Country Status (28)
Country | Link |
---|---|
US (1) | US9512169B2 (fr) |
EP (1) | EP2872524B1 (fr) |
JP (1) | JP6196302B2 (fr) |
KR (1) | KR20150036319A (fr) |
CN (1) | CN104428309B (fr) |
AP (1) | AP2014008179A0 (fr) |
AR (1) | AR092025A1 (fr) |
AU (1) | AU2013289344A1 (fr) |
BR (1) | BR112015000443A2 (fr) |
CA (1) | CA2878485A1 (fr) |
CL (1) | CL2015000039A1 (fr) |
CO (1) | CO7160008A2 (fr) |
CR (1) | CR20150007A (fr) |
DO (1) | DOP2015000005A (fr) |
EA (1) | EA201500112A1 (fr) |
EC (1) | ECSP15000868A (fr) |
ES (1) | ES2603258T3 (fr) |
HK (1) | HK1205743A1 (fr) |
IL (1) | IL236581A0 (fr) |
MA (1) | MA37742B1 (fr) |
MX (1) | MX2015000347A (fr) |
PE (1) | PE20150353A1 (fr) |
PH (1) | PH12015500062A1 (fr) |
TN (1) | TN2015000007A1 (fr) |
TW (1) | TW201402596A (fr) |
UY (1) | UY34899A (fr) |
WO (1) | WO2014009274A1 (fr) |
ZA (1) | ZA201500920B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015018071A2 (pt) * | 2013-02-21 | 2017-07-18 | Bayer Pharma AG | estra-1,3,5(10),16-tetraeno-3-carboxamidas |
JP6407415B2 (ja) * | 2014-09-11 | 2018-10-17 | バイエル・ファルマ・アクティエンゲゼルシャフト | 3−窒素または硫黄置換エストラ−1,3,5(10),16−テトラエンakr1c3阻害剤 |
US10167293B2 (en) | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
EP3269373A1 (fr) | 2016-07-11 | 2018-01-17 | Bayer Pharma Aktiengesellschaft | Formes posologiques orales à faible dosage d'un inhibiteur de akr1c3 pour le traitement des maladies |
US20200085791A1 (en) | 2016-12-19 | 2020-03-19 | Bayer Pharma Aktiengesellschaft | [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones |
TW201825478A (zh) | 2016-12-19 | 2018-07-16 | 德商拜耳製藥公司 | [4-(苯基磺醯基)哌嗪-1--基](1h-1,2,3-***-4-基)甲酮 |
WO2018114672A1 (fr) | 2016-12-19 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | [4-(phénylsulfonyl)pipérazin-1-yl](1h-1,2,3-triazol-4-yl)méthanones |
EP3421483A1 (fr) | 2017-06-29 | 2019-01-02 | Bayer Pharma Aktiengesellschaft | Nouveaux dérivés 17-beta-hétéroaryle des stéroïdes comme inhibiteurs de akr1c3 |
CN110693892A (zh) * | 2018-07-09 | 2020-01-17 | 深圳艾欣达伟医药科技有限公司 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
CN110272465A (zh) * | 2019-07-15 | 2019-09-24 | 成都贝诺科成生物科技有限公司 | 阿比特龙衍生物、其制备方法与应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633893B1 (fr) * | 1992-03-31 | 1999-11-24 | Btg International Limited | Stero des substitues-17 utiles pour le traitement du cancer |
US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
IL122740A (en) | 1997-01-15 | 2003-09-17 | Akzo Nobel Nv | 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them |
BR9809748A (pt) | 1997-04-07 | 2000-06-20 | American Home Prod | Estra-5(10), 7-dienos com atividade estrogênica |
BR9908592A (pt) | 1998-03-11 | 2001-04-24 | Endorech Inc | Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit |
JP2002522380A (ja) | 1998-08-07 | 2002-07-23 | アンドルシェルシュ・インコーポレイテッド | タイプ33α−ヒドロキシステロイドデヒドロゲナーゼの阻害 |
US6953785B2 (en) * | 2000-04-24 | 2005-10-11 | Kyowa Hakko Kogyo Co., Ltd. | Estra-1,3,5(10)-triene derivatives |
WO2005089256A2 (fr) | 2004-03-12 | 2005-09-29 | Entremed, Inc. | Agents anti-angiogeniques |
CN101395134B (zh) | 2006-03-02 | 2011-08-31 | 安斯泰来制药有限公司 | 17β-羟类固醇脱氢酶5型抑制剂 |
RU2453554C2 (ru) | 2006-11-30 | 2012-06-20 | Зольвай Фармасьютиклз Гмбх | Замещенные производные эстратриена как ингибиторы 17бета hsd |
WO2008077810A2 (fr) | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Dérivés de spiropipéridine |
KR20100046107A (ko) | 2007-07-24 | 2010-05-06 | 아스텔라스세이야쿠 가부시키가이샤 | 벤즈이미다졸 유도체 |
DE102011083725A1 (de) * | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
-
2013
- 2013-07-05 US US14/414,386 patent/US9512169B2/en not_active Expired - Fee Related
- 2013-07-05 JP JP2015520927A patent/JP6196302B2/ja not_active Expired - Fee Related
- 2013-07-05 EP EP13734744.9A patent/EP2872524B1/fr active Active
- 2013-07-05 CN CN201380036684.4A patent/CN104428309B/zh not_active Expired - Fee Related
- 2013-07-05 BR BR112015000443A patent/BR112015000443A2/pt not_active IP Right Cessation
- 2013-07-05 CA CA2878485A patent/CA2878485A1/fr not_active Abandoned
- 2013-07-05 ES ES13734744.9T patent/ES2603258T3/es active Active
- 2013-07-05 WO PCT/EP2013/064257 patent/WO2014009274A1/fr active Application Filing
- 2013-07-05 MX MX2015000347A patent/MX2015000347A/es unknown
- 2013-07-05 KR KR20157002707A patent/KR20150036319A/ko not_active Application Discontinuation
- 2013-07-05 AP AP2014008179A patent/AP2014008179A0/xx unknown
- 2013-07-05 AU AU2013289344A patent/AU2013289344A1/en not_active Abandoned
- 2013-07-05 EA EA201500112A patent/EA201500112A1/ru unknown
- 2013-07-05 PE PE2015000018A patent/PE20150353A1/es not_active Application Discontinuation
- 2013-07-10 UY UY0001034899A patent/UY34899A/es not_active Application Discontinuation
- 2013-07-10 TW TW102124795A patent/TW201402596A/zh unknown
- 2013-07-10 AR ARP130102438A patent/AR092025A1/es unknown
-
2015
- 2015-01-05 IL IL236581A patent/IL236581A0/en unknown
- 2015-01-07 TN TNP2015000007A patent/TN2015000007A1/fr unknown
- 2015-01-07 MA MA37742A patent/MA37742B1/fr unknown
- 2015-01-08 CL CL2015000039A patent/CL2015000039A1/es unknown
- 2015-01-09 DO DO2015000005A patent/DOP2015000005A/es unknown
- 2015-01-09 CO CO15004249A patent/CO7160008A2/es unknown
- 2015-01-09 PH PH12015500062A patent/PH12015500062A1/en unknown
- 2015-01-09 CR CR20150007A patent/CR20150007A/es unknown
- 2015-01-09 EC ECIEPI2015868A patent/ECSP15000868A/es unknown
- 2015-02-09 ZA ZA2015/00920A patent/ZA201500920B/en unknown
- 2015-07-06 HK HK15106384.4A patent/HK1205743A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1205743A1 (en) | 2015-12-24 |
CN104428309A (zh) | 2015-03-18 |
JP6196302B2 (ja) | 2017-09-13 |
CO7160008A2 (es) | 2015-01-15 |
EP2872524A1 (fr) | 2015-05-20 |
ES2603258T3 (es) | 2017-02-24 |
DOP2015000005A (es) | 2015-02-15 |
WO2014009274A1 (fr) | 2014-01-16 |
MX2015000347A (es) | 2015-04-14 |
US9512169B2 (en) | 2016-12-06 |
AP2014008179A0 (en) | 2014-12-31 |
TN2015000007A1 (en) | 2016-06-29 |
PH12015500062A1 (en) | 2015-03-02 |
CA2878485A1 (fr) | 2014-01-16 |
CR20150007A (es) | 2015-03-13 |
CL2015000039A1 (es) | 2015-03-27 |
ZA201500920B (en) | 2017-01-25 |
CN104428309B (zh) | 2016-09-14 |
IL236581A0 (en) | 2015-02-26 |
PE20150353A1 (es) | 2015-03-28 |
US20150210734A1 (en) | 2015-07-30 |
UY34899A (es) | 2014-02-28 |
MA37742A1 (fr) | 2016-05-31 |
TW201402596A (zh) | 2014-01-16 |
AU2013289344A1 (en) | 2015-02-05 |
AR092025A1 (es) | 2015-03-18 |
EP2872524B1 (fr) | 2016-08-24 |
KR20150036319A (ko) | 2015-04-07 |
JP2015522050A (ja) | 2015-08-03 |
BR112015000443A2 (pt) | 2017-06-27 |
ECSP15000868A (es) | 2016-01-29 |
EA201500112A1 (ru) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA42376A (fr) | Dérivés d'oxopyridine substitués | |
MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
MA32230B1 (fr) | Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one | |
MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
BR112013008140A8 (pt) | "compostos imidazotriazinona". | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
MA35638B1 (fr) | 2-thiopyrimidinones | |
MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
MA34067B1 (fr) | Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer | |
ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
MA33679B1 (fr) | Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
MA37700B1 (fr) | N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments | |
MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives |